Profound Medical Corp. (TSX:PRN)

Market Cap	192.86M
Revenue (ttm)	17.05M
Net Income (ttm)	-45.93M
Shares Out	30.04M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,335
Average Volume	8,078
Open	6.60
Previous Close	6.42
Day's Range	6.00 - 6.66
52-Week Range	5.58 - 15.75
Beta	0.26
RSI	38.95
Earnings Date	May 8, 2025

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 142
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: PRN

Financial Performance

In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.

Financial numbers in USD